Search Results for "Synthesis Sorafenib"
Original Source: Design, Synthesis and Evaluation of Novel Rhodanine-containing Sorafenib Analogs as Potential Antitumor Agents.
A series of rhodanine-containing sorafenib analogs was designed, synthesized and evaluated for their in-vitro antitumor activity against three cancer cell lines (A549, H460 and HT29). Pharmacological data indicated that some of the target compounds possessed marked antiproliferative activity superior to the reference drug sorafenib, especially the most promising compound 7r (with the IC(50) value of 0.8, 1.3 and 2.8 µM against A549, H460 and HT29 cell lines, respectively). The activity was found to stron...
Matching Channels
Synthesis and Release of Thyroid Hormones
Spectinomycin is an aminocyclitol antibiotic, closely related to the aminoglycosides, produced by the bacterium Streptomyces spectabilis. It is used against gonorrhea infections by interrupting prot...
KYNAMRO (mipomersen sodium) injection is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprote...
Vitamin C is a water-soluble vitamin that is necessary to form collagen; so is implicated in the synthesis of skin, scar tissue, tendons, ligaments, and blood vessels, the healing of wounds, and for...
Drug Discovery - news, views, blogs and reports
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and/or designed. In the past most drugs have been discovered either by identi...
Matching News
Sorafenib beneficial in liver cancer regardless of etiology
NEW YORK (Reuters Health) - Sorafenib improves survival and disease control consistently in patients with advanced hepatocellular carcinoma (HCC) of different etiologies, according to a new report...
Sorafenib Monotherapy Remains Standard in HCC
A large trial has shown that adding erlotinib to sorafenib does not improve outcomes in patients with unresected hepatocellular carcinoma (HCC). Medscape Medical News
Sorafenib add-on fails in advanced nonsquamous NSCLC
NEW YORK (Reuters Health) - In patients with advanced nonsquamous non-small-cell lung cancer (NSCLC), adding sorafenib to first-line gemcitabine/cisplatin did not improve overall survival and was...
Sorafenib can be combined with arterial embolization for treating liver tumors
NEW YORK (Reuters Health) - Sorafenib given concurrently with transarterial chemoembolization (TACE) is safe in patients with intermediate hepatocellular carcinoma (HCC) and does not lead to any u...
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory ...
Key Clinical Endpoints Met: JX-594 can be Safely and Efficiently Delivered Through Systemic Route, and Standard-of-Care Sorafenib Can Be Safely Administered Sequentially After JX-594, Opening Door to...
Sorafenib does not improve survival in metastatic melanoma
NEW YORK (Reuters Health) - Sorafenib added to carboplatin and paclitaxel does not improve overall survival in patients with metastatic melanoma.
Sorafenib could be effective against multiple myeloma
Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of th...
Sorafenib benefits select HCC patients with cirrhosis
NEW YORK (Reuters Health) - Single-agent sorafenib improves outcomes for select patients with advanced hepatocellular carcinoma (HCC) and underlying Child-Pugh B liver cirrhosis, researchers from...
Matching PubMed Articles
PURPOSE: Sorafenib is primarily metabolized in the liver, by CYP3A4-mediated oxidation and UGT1A9-mediated glucuronidation. However, there is little information about the pharmacokinetic interaction o...
PURPOSE: Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is highly bound to plasma proteins (>99.5%). Little is known about the influence of variations in sorafenib protein binding on its...
Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
BACKGROUND: The oral multikinase inhibitor sorafenib is the new reference standard for the treatment of advanced hepatocellular carcinoma. Only few data are available on the use of sorafenib in cholan...
Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers.
The multikinase inhibitor sorafenib is therapeutically used in various malignancies. Multiple cutaneous side effects are well described but recent reports indicated a possible association of epithelia...
Purpose Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). We conducted a phase 1 study of sorafenib plus S-1...
